Vaxart has seen positive safety and immunogenicity data, comparable to that of currently marketed vaccines, from our Phase 1 clinical studies of our H1N1 seasonal influenza tablet vaccine. We are moving forward with further studies of influenza, along with studies of vaccine candidates for other indications.
All Vaxart vaccine trials are conducted by U.S.-based contract research organizations under GCP (good clinical practices). Vaxart vaccines are manufactured under GMP (good manufacturing practices) in the United States by a global manufacturer of biological products. The Vaxart vaccine is administered as a convenient enteric-coated tablet.